In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Companion Diagnostics Move Toward Mainstream Drug Development

Executive Summary

With FDA planning to release guidelines on companion diagnostics by year's end, private sector activity around biomarkers appears ready to accelerate. Pharma companies are taking different strategies to incorporate companion diagnostics into their drug development programs, and experimenting with different applications for co-developed products. The relationship between Pharma and diagnostics companies is evolving, with Pharma leading the way. The pace of dealmaking is picking up, but in negotiating partnerships, both sides are still struggling with how to reconcile their different business models, cost structures, and appetites for risk.
Advertisement

Related Content

FDA Releases Companion Dx Guidance Broad In Scope, Limited In Detail
Personalized Medicine In 2010: Welcome To The Establishment
Personalized Medicine In 2010: Welcome To The Establishment
Medical Device and In Vitro Diagnostics/Research Deal Statistics Quarterly, Q1 2010
Will COX-2 + Biomarker = Success? Novartis Tests the Frontiers of Companion Diagnostics
With DxS, Qiagen Moves into Personalized Medicine
With DxS, Qiagen Moves into Personalized Medicine
Companion Diagnostics Spark Pharma Deals - But Still Mostly For Cancer
Problems With Biomarkers: A Tale of Three Drugs
Problems With Biomarkers: A Tale of Three Drugs

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV003459

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel